2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-144003
    BAY-R 1005 294664-93-0 98%
    BAY-R 1005, an immunoenhancing agent, is a synthetic glycolipid analogue (GLA), which is supposed to modulate antibody synthesis.
    BAY-R 1005
  • HY-144032
    Tyk2-IN-9 2694816-85-6 98%
    Tyk2-IN-9 (Compound 26) is a selective Tyk-2 inhibitor with IC50s of 0.076 and 1.8 nM for TYK2-JH2 and JAK1-JH2, respectively. Tyk2-IN-9 can be used for the research of inflammatory or autoimmune disease.
    Tyk2-IN-9
  • HY-144057
    JAK-IN-17 98%
    JAK-IN-17 is a potent inhibitor of JAK. JAK-IN-17 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2021185305A1, compound 9-1).
    JAK-IN-17
  • HY-144058
    JAK-IN-18 2247925-32-0 98%
    JAK-IN-18 is a potent inhibitor of JAK. JAK-IN-18 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2018204238A1, compound 1).
    JAK-IN-18
  • HY-144072
    MRS4620 2411665-73-9 98%
    MRS4620 is a potent CD73 inhibitor, with a Ki of 0.436 nM. MRS4620 can be use for the research of cancer immunoresearch.
    MRS4620
  • HY-144075
    JAK-IN-19 98%
    JAK-IN-19 is a potent JAK inhibitor (PBMC IFNγ pIC50=7.2 and HLF Eotaxin pIC50=7.7). JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 pIC50=7.0, Aurora B pIC50=5.8).
    JAK-IN-19
  • HY-144087
    TYK2-IN-11 2757009-40-6 98%
    TYK2-IN-11 (Compound 5B) is a selective Tyk-2 inhibitor with IC50s of 0.016 and 0.31 nM for TYK2-JH2 and JAK1-JH2, respectively. TYK2-IN-11 can be used for the research of inflammatory or autoimmune disease.
    TYK2-IN-11
  • HY-144097
    HER2-IN-8 2704630-49-7 98%
    HER2-IN-8 is a HER-2 inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation.
    HER2-IN-8
  • HY-144126
    S1P1 agonist 5 2760666-20-2 98%
    S1P1 agonist 5 is a selective and orally active S1P1 agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS).
    S1P1 agonist 5
  • HY-144169
    DHODH-IN-19 2742675-85-8 98%
    DHODH-IN-19 is a potent inhibitor of DHODH. DHODH is present in the inner membrane of human mitochondria and is an iron-containing flavin-dependent enzyme. DHODH-IN-19 inhibits tumor growth. DHODH-IN-19 has the potential for the research of cancer and inflammation disease (extracted from patent WO2021238881A1, compound 1).
    DHODH-IN-19
  • HY-144194
    MIF-IN-2 2756410-57-6 98%
    MIF-IN-2 is a migration inhibitory factor (MIF) inhibitor extracted from patent WO2021258272A1 compound 1. MIF-IN-2 can be used for the research of immune inflammation-related diseases.
    MIF-IN-2
  • HY-144195
    MIF-IN-3 2756410-83-8 98%
    MIF-IN-3 is a migration inhibitory factor (MIF) inhibitor extracted from patent WO2021258272A1 compound 31. MIF-IN-3 can be used for the research of immune inflammation-related diseases.
    MIF-IN-3
  • HY-144215
    TLR8 agonist 4 2761697-69-0 98%
    TLR8 agonist 4 showed effective inhibition on wild-type and drug-resistant (lamivudine and entecavir) HBV strains. The IC50 values are 0.15 and 0.10 respectively μM.
    TLR8 agonist 4
  • HY-144220
    NLRP3/AIM2-IN-1 98%
    NLRP3/AIM2-IN-1 is a thermal sepsis inhibitor with an < b > IC < sub > 50 < / sub > < / b > value of 3.136 ± 0.7667 μ M.
    NLRP3/AIM2-IN-1
  • HY-144229
    trans-Cephalosporin 2757462-75-0 98%
    Trans substituted cephalosporin is an effective NDM-1 inhibitor，with an IC50 value of 0.13 μM.
    trans-Cephalosporin
  • HY-144237
    BRP-201 2227434-74-2 98%
    Brp-201 is considered as a promising therapeutic target for the next generation of anti-inflammatory drugs in the research of inflammatory diseases. It is a new, effective and selective inhibitor of mPGES-1 with an IC50 value of 0.42 μM.
    BRP-201
  • HY-144238
    mPGES1-IN-6 2914158-00-0 98%
    mPGES1-IN-6 is a potent inhibitor of mPGES-1 (IC50=0.03 μM), a typical anti-inflammatory drug target.
    mPGES1-IN-6
  • HY-144255
    Antibacterial agent 70 98%
    Antibacterial agent 70 is a new dihydropyrimidinone imidazole hybrid antibacterial agent, and its < b > MIC < / b > value is 0.5 μg/mL
    Antibacterial agent 70
  • HY-144265
    PDE4-IN-5 2768626-06-6 98%
    PDE4-IN-5 (compound 33a) is a potent and selective PDE4 inhibitor (IC50=3.1 nM). PDE4-IN-5 has favorable skin permeability and a well-characterized binding mechanism. Anti-psoriasis effect.
    PDE4-IN-5
  • HY-144276
    RIPK1-IN-11 2173557-02-1 98%
    RIPK1-IN-11 is a potent and orally active RIPK1 inhibitor (Kd=9.2 nM; IC50=67 nM). RIPK1-IN-11 inhibits necroptosis in both human and mouse cells (EC50=17-30 nM). Anti-inflammatory activity.
    RIPK1-IN-11
Cat. No. Product Name / Synonyms Application Reactivity